BRIDGE CAR T™

3 Regional Webinars! Please register for both Part 1 and Part 2 of your local sessions below!

Program Overview

Non-Hodgkins lymphoma (NHL) is one of the most common cancers in the United States, with nearly 80,000 new diagnoses estimated for 2026. Comprised of multiple subtypes, NHL can be indolent or progress rapidly, with the more aggressive subtypes accounting for 60% of all cases. While many cases of NHL can be successfully treated with chemoimmunotherapy, most patients will experience relapses, requiring further lines of treatment. In more recent years, the development and approval of newer therapies like chimeric antigen receptor (CAR) T-cells have expanded the options available to patients who experience relapsed/refractory (R/R) NHL. With such a vast and rapidly evolving treatment landscape, it can be exceedingly difficult for oncologists, particularly in the community setting, to identify patients who may be candidates for CAR T-cell therapies, and to understand the process involved in transferring care to appropriate treatment centers. The BRIDGE CAR T: Building Bridges Between Treatment Centers and Community Oncologists to Overcome Barriers in CAR T-Cell Therapy workshop series has been designed to meet clinicians where they are and close education gaps through didactic lectures, expert-led discussions, case-based learnings, and clinician and patient support tools. This series will foster connections between community oncologists and CAR T-cell therapy centers, in an effort to empower clinicians and improve patient care in the R/R NHL treatment space. 

Workshop 1 Agenda

• Introduction
• FDA-Approved CAR T-Cell Therapies
• Identification of Eligible Patients
• Strategies to Overcome Barriers to CAR T-Cell Implementation
• CAR T-Cell Therapy-Associated Adverse Events, (AEs)
• Concluding Comments

Workshop 2 Agenda

• Introduction
• Brief Review of CAR T-Cell Therapy for NHLs
• Case 1: A Patient With Diffuse Large B-cell Lymphoma (DLBCL): Exploring CAR T-Cell Therapy
• Case 2: A Patient With Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL): Exploring CAR T-Cell Therapy in Indolent NHL
• Case 3: A Patient With Chronic Lymphocytic Leukemia (CLL): Recognizing and Mitigating Immune Effector Cell-Associated Neurotoxicity Syndrome (ICAN) and Cytokine Release Syndrome (CRS)
• Case 4: A Patient With Mantle Cell Lymphoma (MCL): Managing Potential Longer-Term AEs
• Concluding Comments